Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021 Corrects statistical analysis from previous exploratory Phase 2 study—no...
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study SAN DIEGO, Calif., June 7, 2021 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000...
ADDEX STARTS PHASE 2 CLINICAL STUDY OF ADX71149 FOR EPILEPSY First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting – Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided...
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application...
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic Data...
Recent Comments